|
|
Vaccine Detail
|
HPV E6/E7-encoding Semliki Forest Virus Vaccine Vvax001 |
| Vaccine Information |
- Vaccine Name: HPV E6/E7-encoding Semliki Forest Virus Vaccine Vvax001
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: HPV-derived tumor antigens (viral oncoproteins E6 and E7) (NCT03141463; NCIT_C148539)
- Immunization Route: Intramuscular injection (i.m.)
- Description: vaccine consisting of a recombinant, attenuated, replication-incompetent form of the Semliki Forest Virus (SFV) vector encoding the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV), with potential immunomodulating and antineoplastic activities. The vaccine induces expression of the E6/E7 proteins and stimulates both the innate and the adaptive immune system, resulting in a potent cytotoxic T-lymphocyte (CTL) response against and lysis of tumor cells expressing HPV E6 and E7. (NCIT_C148539) The vaccine may help to treat patients with a history of (pre) malignant cervical lesions. (NCT03141463)
|
| Host Response |
|
|
| References |
NCIT_C148539: HPV E6/E7-encoding Semliki Forest Virus Vaccine Vvax001 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148539]
NCT03141463: Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions [https://clinicaltrials.gov/study/NCT03141463]
|
|
